GlassScriptPhysician profile
Vincent Valentine
NPI 1972530608
$5,998.24
in general payments reported to CMS, 2019-2025
29 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,697 · 2020: $44.02 · 2022: $57.40 · 2023: $741 · 2024: $1,060 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $2,637.74 | 2019 | |
| Insmed, INC. | $578.53 | 2019 | |
| La Jolla Pharmaceutical Company | $353.68 | 2023-2025 | Giapreza, Xacduro |
| United Therapeutics Corporation | $323.34 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| Mallinckrodt Hospital Products INC. | $250.35 | 2023-2024 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $230.87 | 2023-2025 | Andexxa, Tezspire |
| Allergan, INC. | $208.28 | 2019 | |
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| Astellas Pharma US INC | $145.19 | 2019-2025 | Cresemba |
| Alcresta Therapeutics, INC. | $142.46 | 2024 | Relizorb |
| Eurofins Viracor, LLC | $123.04 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $112.51 | 2023-2025 | Uptravi, Opsumit |
| Amgen INC. | $97.24 | 2024 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $86.92 | 2024-2025 | Aralast, Glassia |
| Impulse Dynamics (USA) INC. | $67.65 | 2024 | Optimizer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $64.55 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.97 | 2022-2023 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Baxter Healthcare | $50.79 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Shionogi INC | $48.73 | 2024-2025 | Fetroja |
| Abbvie INC. | $44.58 | 2023 | Teflaro |
| Astellas Pharma Global Development | $44.02 | 2020 | |
| Fresenius USA Marketing, INC. | $35.82 | 2024 | Nxstage System One |
| Ultragenyx Pharmaceutical INC. | $29.98 | 2023 | |
| Merck Sharp & Dohme LLC | $23.37 | 2023 | Recarbrio, Zerbaxa |
| Mallinckrodt Enterprises LLC | $22.95 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.74 | 2024 | |
| Lilly USA, LLC | $17.60 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $13.67 | 2023 | |
| Novo Nordisk INC | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Valentine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.